US Map / Tennessee
State TN

Clinical Trials in Tennessee

Tennessee is home to a significant concentration of clinical research activity, with academic medical centers, community hospitals, and specialized research clinics serving as active trial sites across a broad range of medical conditions. The studies listed here have at least one enrolled site in Tennessee and represent Phase 1 through Phase 4 research sponsored by NIH, pharmaceutical companies, device manufacturers, and independent investigators.

Right now ClinicalMetric tracks 312 actively recruiting studies with Tennessee sites out of 312 registered in total. The busiest research areas in Tennessee are Breast Cancer, Endometrial Cancer, Advanced Solid Tumors. Leading sponsors running trials in the state include Vanderbilt University Medical Center, St. Jude Children's Research Hospital, AstraZeneca. By stage, Tennessee trials break down as Phase 1 (80), Phase 2 (93), Phase 3 (93), Phase 4 (12).

All trial data is sourced directly from ClinicalTrials.gov and updated daily. Recruiting status, eligibility criteria, enrollment targets, and contact information are included for each study. Patients and caregivers should review the full eligibility criteria on each trial listing — or consult their treating physician — before contacting a study site.

Total Trials
312
Recruiting Now
312
← Back to US Map
Top Conditions in Tennessee
Breast Cancer (9)Endometrial Cancer (7)Advanced Solid Tumors (5)Non-Small Cell Lung Cancer (5)Obesity (5)Ovarian Cancer (5)Acute Myeloid Leukemia (5)Colorectal Cancer (4)Pancreatic Cancer (4)Heart Failure (4)Solid Tumors (4)Solid Tumor (4)

Frequently Asked Questions — Clinical Trials in Tennessee

How many clinical trials are currently recruiting in Tennessee?
ClinicalMetric currently tracks 312 actively recruiting clinical trials with at least one location in Tennessee. The total number of registered studies—including active but not currently enrolling trials—is 312. Trial availability is updated daily from ClinicalTrials.gov, and new studies open enrollment regularly throughout the year.
What types of clinical trials are available in Tennessee?
Tennessee hosts clinical trials across a broad range of medical conditions, including Breast Cancer, Endometrial Cancer, Advanced Solid Tumors, and many others. Trials range from Phase 1 early-safety studies to Phase 4 post-approval surveillance, as well as observational and behavioral research. Academic medical centers, community hospitals, and specialized research clinics throughout Tennessee serve as trial sites for studies sponsored by NIH, pharmaceutical companies, and independent investigators.
How do I join a clinical trial near me in Tennessee?
To join a clinical trial in Tennessee, browse the recruiting studies listed on this page, review the eligibility criteria for each trial, and contact the study site directly. Your primary care physician or specialist can also refer you to clinical trials relevant to your diagnosis. Many academic medical centers in Tennessee maintain dedicated clinical trials offices that can match you with appropriate studies based on your medical profile and diagnosis.

Recruiting Trials in Tennessee

NCT05313165 N/A
Recruiting
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-St...
Condition
Critical Limb Ischemia
Enrollment
100 pts
Location
United States
Sponsor
LimFlow, Inc.
View Trial →
NCT06458036 Phase 2
Recruiting
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Condition
Differentiated Thyroid Cancer
Enrollment
13 pts
Location
United States
Sponsor
Children's Hospital of Philade
View Trial →
NCT07227311 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combinati...
Condition
Multiple Myeloma
Enrollment
200 pts
Location
United States, France, Germany
Sponsor
GlaxoSmithKline
View Trial →
NCT06046495 Phase 1
Recruiting
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Condition
Non-Small Cell Lung Cancer
Enrollment
81 pts
Location
United States
Sponsor
Avistone Biotechnology Co., Lt
View Trial →
NCT00575081 N/A
Recruiting
Physiological Brain Atlas Development
Condition
Parkinson's Disease
Enrollment
5,000 pts
Location
United States
Sponsor
Vanderbilt University Medical
View Trial →
NCT01904851 N/A
Recruiting
Multi-Center Registry for Peripheral Arterial Disease Interventions and Outcomes
Condition
Peripheral Arterial Disease
Enrollment
14,000 pts
Location
United States
Sponsor
Baylor Research Institute
View Trial →
NCT06283966 Phase 3
Recruiting
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fum...
Condition
COPD (Chronic Obstructive Pulmonary Disease)
Enrollment
5,000 pts
Location
United States, Argentina, Australia
Sponsor
AstraZeneca
View Trial →
NCT07566156 Phase 3
Recruiting
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradioth...
Condition
Urothelial Cancer
Enrollment
390 pts
Location
United States, Canada
Sponsor
Astellas Pharma Global Develop
View Trial →
NCT05125302 Phase 3
Recruiting
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets f...
Condition
Migraine
Enrollment
1,059 pts
Location
United States, Puerto Rico
Sponsor
AbbVie
View Trial →
NCT06554795 Phase 1, Phase 2
Recruiting
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
Condition
Solid Tumor, Adult
Enrollment
360 pts
Location
United States, Australia, China
Sponsor
DualityBio Inc.
View Trial →
NCT06427941 Phase 1, Phase 2
Recruiting
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With o...
Condition
Metastatic Hepatocellular Carcinoma
Enrollment
630 pts
Location
United States, Brazil, China
Sponsor
BeOne Medicines
View Trial →
NCT06940739 Phase 1, Phase 2
Recruiting
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanc...
Condition
Unresectable Melanoma
Enrollment
42 pts
Location
United States, Australia
Sponsor
Iovance Biotherapeutics, Inc.
View Trial →
NCT06692738 Phase 3
Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for...
Condition
Non-small Cell Lung Cancer
Enrollment
1,160 pts
Location
United States, Argentina, Australia
Sponsor
AstraZeneca
View Trial →
NCT07113210 Phase 4
Recruiting
Quality of Life in Presbyopic Patients Who Are Treated With Qlosi
Condition
Presbyopia
Enrollment
36 pts
Location
United States
Sponsor
Southern College of Optometry
View Trial →
NCT07684235 Phase 3
Recruiting
Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of ...
Condition
Obesity
Enrollment
3,200 pts
Location
United States, Australia, Japan
Sponsor
Amgen
View Trial →
NCT05624996 Phase 3
Recruiting
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for...
Condition
Locally Advanced Lung Non-Small Cell Carcinoma
Enrollment
474 pts
Location
United States, Canada
Sponsor
NRG Oncology
View Trial →
NCT07121946 Phase 1
Recruiting
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-H...
Condition
Non-Hodgkin Lymphoma Refractory/ Relapsed
Enrollment
42 pts
Location
United States
Sponsor
LTZ Therapeutics, Inc.
View Trial →
NCT06842498 Phase 2
Recruiting
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate...
Condition
Metastatic Castration-Resistant Prostate Cancer
Enrollment
75 pts
Location
United States
Sponsor
Kyntra Bio
View Trial →
NCT06501625 Phase 1, Phase 2
Recruiting
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Pa...
Condition
Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation
Enrollment
52 pts
Location
United States, Australia, Brazil
Sponsor
Institut de Recherches Interna
View Trial →
NCT05379985 Phase 1, Phase 2
Recruiting
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Muta...
Condition
Non-small Cell Lung Cancer (NSCLC)
Enrollment
754 pts
Location
United States
Sponsor
Revolution Medicines, Inc.
View Trial →
NCT07673016 N/A
Recruiting
Specimen Collection for Validation of UroAmp: A Next Generation Sequencing Platf...
Condition
Bladder Cancer
Enrollment
2,500 pts
Location
United States, Puerto Rico
Sponsor
Convergent Genomics, Inc.
View Trial →
NCT06745908 Phase 3
Recruiting
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhi...
Condition
NSCLC Stage IV
Enrollment
507 pts
Location
United States, Canada, United Kingdom
Sponsor
ImmunityBio, Inc.
View Trial →
NCT06872125 Phase 3
Recruiting
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevu...
Condition
Dravet Syndrome
Enrollment
170 pts
Location
United States, China, France
Sponsor
Stoke Therapeutics, Inc
View Trial →
NCT06822426 Phase 3
Recruiting
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodst...
Condition
Central Line Associated Blood Stream Infections (CLABSI)
Enrollment
200 pts
Location
United States, Turkey (Türkiye)
Sponsor
CorMedix Therapeutics
View Trial →
NCT05899608 Phase 3
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patie...
Condition
Non-Small Cell Lung Cancer
Enrollment
1,600 pts
Location
United States, Belgium, Canada
Sponsor
Summit Therapeutics
View Trial →
Page 3 of 13 — 312 trials total
← Prev Next →
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology